Barclays PLC Acquires 1,528 Shares of XOMA Co. (NASDAQ:XOMA)

Barclays PLC raised its stake in XOMA Co. (NASDAQ:XOMA) by 13.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,784 shares of the biotechnology company’s stock after acquiring an additional 1,528 shares during the period. Barclays PLC owned approximately 0.11% of XOMA worth $336,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in XOMA. JPMorgan Chase & Co. raised its stake in XOMA by 238.9% during the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock valued at $318,000 after purchasing an additional 8,522 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of XOMA in the fourth quarter worth about $206,000. Renaissance Technologies LLC increased its position in shares of XOMA by 89.8% during the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock worth $423,000 after acquiring an additional 7,619 shares during the period. Rhumbline Advisers raised its position in XOMA by 18.1% during the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 1,699 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of XOMA by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 23,113 shares of the biotechnology company’s stock valued at $607,000 after acquiring an additional 1,276 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

XOMA Stock Performance

XOMA opened at $24.19 on Friday. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a 52-week low of $18.35 and a 52-week high of $35.00. The company has a market cap of $289.14 million, a price-to-earnings ratio of -6.95 and a beta of 0.89. The firm’s fifty day simple moving average is $21.48 and its two-hundred day simple moving average is $25.56.

XOMA (NASDAQ:XOMA) last issued its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). The business had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. Equities analysts anticipate that XOMA Co. will post -1.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on XOMA shares. StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a report on Friday, April 11th. HC Wainwright restated a “buy” rating and set a $104.00 price objective on shares of XOMA in a research note on Friday, March 28th. Finally, Benchmark initiated coverage on XOMA in a research note on Thursday, April 17th. They issued a “buy” rating and a $35.00 target price on the stock.

Insider Activity at XOMA

In other XOMA news, Director Joseph M. Limber bought 5,243 shares of the business’s stock in a transaction on Monday, April 7th. The stock was bought at an average price of $25.60 per share, with a total value of $134,220.80. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $256,000. The trade was a 110.22 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CIO Bradley Sitko purchased 2,000 shares of the firm’s stock in a transaction dated Monday, April 7th. The stock was acquired at an average cost of $24.70 per share, for a total transaction of $49,400.00. Following the purchase, the executive now owns 5,045 shares in the company, valued at approximately $124,611.50. The trade was a 65.68 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 29,312 shares of company stock valued at $735,061. 9.10% of the stock is owned by company insiders.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.